Sara Deringer-Kohorst, PA
Payments from drug & device makers
Across 40 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$146
- Novo Nordisk$123
- Otsuka America Pharmaceutical, Inc.$106
- GSK$74
- AstraZeneca$62
- Amgen$50
- plus $164 from 7 others
What the payments were for
- Food & beverage$724100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 7 | $146 |
| Novo Nordisk | 6 | $123 |
| Otsuka America Pharmaceutical, Inc. | 5 | $106 |
| GSK | 5 | $74 |
| AstraZeneca | 4 | $62 |
| Amgen | 3 | $50 |
| Kowa Pharmaceuticals America, Inc. | 3 | $44 |
| Bayer | 2 | $39 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $18 |
| Exact Sciences | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
How this compares
$724 in reported general payments places this provider in the 55th percentile of 755 medical providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $18,147 |
| JardianceEmpagliflozin | 15 | $14,613 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,311 |
| Simvastatin | 48 | $631 |
| Metoprolol Succinate | 35 | $590 |
| Levothyroxine Sodium | 53 | $537 |
| Rosuvastatin Calcium | 28 | $520 |
| Irbesartan | 12 | $468 |
| Amlodipine Besylate | 78 | $464 |
| Lisinopril | 66 | $443 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 21 | $442 |
| Omeprazole | 39 | $433 |
| Montelukast Sodium | 20 | $381 |
| Duloxetine Hcl | 22 | $369 |
| Baclofen | 29 | $350 |
Paid to pharmacies, not to this prescriber.
Other medical in Ovid
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$66K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- Robert DemeesterRoyal Oak$27K
- John BrabantDetroit$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.